CINECA IRIS Institutional Research Information System

BUDA, GABRIELE
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.928
EU - Europa 3.733
AS - Asia 1.641
AF - Africa 152
OC - Oceania 16
Continente sconosciuto - Info sul continente non disponibili 7
SA - Sud America 5
Totale 14.482
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 8.723
IT - Italia 1.623
CN - Cina 761
SE - Svezia 671
DE - Germania 406
SG - Singapore 397
BG - Bulgaria 349
TR - Turchia 221
CA - Canada 204
GB - Regno Unito 164
VN - Vietnam 137
UA - Ucraina 115
FI - Finlandia 105
CI - Costa d'Avorio 84
RU - Federazione Russa 84
HK - Hong Kong 68
CH - Svizzera 50
FR - Francia 47
AT - Austria 42
IN - India 38
SN - Senegal 32
BE - Belgio 23
NG - Nigeria 19
AU - Australia 14
EG - Egitto 11
CZ - Repubblica Ceca 9
NL - Olanda 9
ES - Italia 7
IE - Irlanda 7
JP - Giappone 7
BJ - Benin 6
EU - Europa 6
ID - Indonesia 5
BR - Brasile 4
PL - Polonia 4
LT - Lituania 3
RO - Romania 3
EE - Estonia 2
GR - Grecia 2
HU - Ungheria 2
NZ - Nuova Zelanda 2
PT - Portogallo 2
SA - Arabia Saudita 2
A1 - Anonimo 1
BD - Bangladesh 1
DK - Danimarca 1
GY - Guiana 1
HR - Croazia 1
IR - Iran 1
LV - Lettonia 1
MX - Messico 1
MY - Malesia 1
PK - Pakistan 1
RS - Serbia 1
TW - Taiwan 1
Totale 14.482
Salva come PNG Salva come JPEG
Città #
Woodbridge 1.283
Fairfield 936
Ann Arbor 745
Santa Clara 708
Chandler 644
Houston 599
Serra 522
Milan 463
Seattle 429
Ashburn 427
Wilmington 371
Sofia 349
Cambridge 332
Beijing 288
Singapore 224
New York 221
Boardman 196
Ottawa 189
Princeton 182
Jacksonville 174
Florence 147
Izmir 143
Lawrence 142
Medford 137
Nanjing 105
Abidjan 84
Des Moines 81
Istanbul 72
Hong Kong 65
Dong Ket 58
Bremen 54
San Diego 51
Rome 50
Dearborn 49
Bern 47
Frankfurt am Main 42
Pisa 42
Redwood City 36
Vienna 35
London 34
Dakar 32
Nanchang 32
Hebei 30
Shenyang 28
Boulder 26
Changsha 24
Jüchen 24
Brussels 23
Lancaster 23
Ogden 22
Los Angeles 21
Kunming 20
Shanghai 20
Jiaxing 19
Lagos 19
Fuzhou 18
Hefei 15
Norwalk 14
Nürnberg 13
Guangzhou 11
Phoenix 11
Quanzhou 11
San Jose 11
Alessandria 10
Auburn Hills 10
Falls Church 10
Washington 10
Hangzhou 9
Orange 9
Dallas 8
Tianjin 8
Capannori 7
Düsseldorf 7
Kent 7
Phagwāra 7
Pune 7
Sydney 7
Toronto 7
Wuhan 7
Chicago 6
Cotonou 6
Detroit 6
Lanzhou 6
Lucca 6
San Francisco 6
Vicopisano 6
Chengdu 5
Fremont 5
Breda 4
Cascina 4
Castellazzo Bormida 4
Cologno Monzese 4
Genoa 4
Helsinki 4
Jakarta 4
Jinan 4
Rignano 4
Warsaw 4
Amsterdam 3
Bari 3
Totale 11.451
Salva come PNG Salva come JPEG
Nome #
Atypical APL including multiple translocations and abnormal response to micronuclei induction test 212
CD45 expression in low-grade B-cell non-Hodgkin's lymphomas 193
Bone marrow infiltration in B-cell non-Hodgkin's lymphomas: comparison between flow cytometry and bone marrow biopsy, RECENTI PROGRESSI IN MEDICINA 178
Identification of miRSNPs associated with the risk of multiple myeloma 176
Human autologous plasma-derived clot as a biological scaffold for mesenchymal stem cells in treatment of orthopedic healing. 170
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia. 168
Response to chemotherapy and tandem autologous transplantation of multiple myeloma patients and GSTP1 and TYMS polymorphisms 163
CHEMOIMMUNOTHERAPY REGIMEN OF FLUDARABINE, CYCLOPHOSPHAMIDE, AND RITUXIMAB FOLLOWED BY ALEMTUZUM- AB AS INITIAL THERAPY FOR CHRONIC LYMPHOCYTIC LEUKAEMIA: A VALID APPROACH FOR ERADICATION OF MINIMAL RESIDUAL DISEASE 160
Could age modify the effect of genetic variants in IL6 and TNF-a genes in multiple myeloma? 160
Infliximab treatment of grade IV skin acute graft versus host disease 158
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 157
Comprehensive investigation of genetic variation in the 8q24 region and multiple myeloma risk in the IMMEnSE consortium. 157
Genetics and molecular epidemiology of multiple myeloma: the rationale for the IMMEnSE consortium (review). 154
EFFICACY OF FLUDARABINE, CYCLOPHOSPHAMIDE, RITUXIMAB (FCR) REGIMEN FOL- LOWED BY ALEMTUZUMAB AS IN VIVO PURGING TOOL FOR PATIENTS WITH ADVANCED CHRONIC LYMPHOCYTIC LEUKEMIA 150
Unexpected cardiotoxicity in haematological bortezomib treated patients 146
VDTPACE As Salvage Therapy For Heavily Pretreated MM Patients 143
Association of PIM gene translocation and TELAML1 rearrangement., LEUKEMIA RESEARCH,vol. Leuk Res. 2007 Dec;31(12):1761-2 141
Polymorphisms in regulators of xenobiotic transport and metabolism genes PXR and CAR do not affect multiple myeloma risk: a case-control study in the context of the IMMEnSE consortium. 140
Type 2 diabetes-related variants influence the risk of developing multiple myeloma: results from the IMMEnSE consortium. 139
Role of Yttrium-90 Ibritumomab Tiuxetan (Zevalin®) in Inducing and Maintaining Complete Molecular Response in B Non Hodgkin’s Lymphoma Patients in Clinical Complete Remission after Chemotherapy Regimen. 135
2CdA chemotherapy and rituximab in the treatment of marginal zone lymphoma 134
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). Ann Oncol. 2010 Apr;21(4):851-4. Epub 2009 Oct 13. 133
Vascular Endothelial Growth Factor Polymorphisms in Mantle Cell Lymphoma 131
Vorinostat and bortezomib significantly inhibit WT1 gene expression in MO7-e and P39 cell lines 129
Unusual association of endometrial cancer and multiple myeloma 128
Other mechanisms to explain the role of reduced folate carrier in cancer 127
Lenograstim reduces the incidence of febrile episodes, when compared with filgrastim, in multiple myeloma patients undergoing stem cell mobilization 127
Folic acid fortification and cancer risk 125
INDUCTION OF COMPLETE MOLECULAR RESPONSE WITH YTTRIUM-90 IBRITUMOMAB TIUXETAN (ZEVALIN®) IN B CELL NON HODGKIN’S LYMPHOMA PATIENTS AFTER THE ACHIEVEMENT OF A COMPLETE CLINICAL RESPONSE WITH CHEMOTHERAPY REGIMEN 124
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in ch 124
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients 124
A therapy resistant myelodysplastic syndrome characterized by the presence of the rare reciprocal translocation t(3;12)(q26.2;p13) 124
MDR1 polymorphism influences the outcome of multiple myeloma patients 124
Impact of polymorphic variation at 7p15.3, 3p22.1 and 2p23.3 loci on risk of multiple myeloma. 123
Aggressive Non Hodgkin lymphoma'patients Treated by High Dose Chemotherapy and Immunotherapy Has a Lower Relapse Rate: Results of a Computer Science Analysis. 123
Abnormal phenotype of bone marrow plasma cells in patients with chronic myeloid leukemia undergoing therapy with Imatinib 123
VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) POLYMORPHISMS AND THEIR RELATIONSHIP WITH CLINICAL OUTCOME OF MANTLE CELL LYMPHOMA 122
MDR1 polymorphism influences the outcome of multiple myeloma patients 122
Pharmacogenetic Study on Multiple Myeloma Patients Treated with DAV Regimen and Autologous Stem Cell Transplantation. 121
Lack of association of NQO1 and GSTP1 polymorphisms with multiple myeloma risk 121
NQO1*2 polymorphism and response to treatment in patients with multiple myeloma 119
A whole blood flow cytometric method to evaluate F-actin polymerization in neutrophils 118
Fludarabine, Bortezomib, Myocet and rituximab chemotherapy in relapsed and refractory mantle cell lymphoma 118
Significant efficacy of 2-CdA with or without rituximab in the treatment of splenic marginal zone lymphoma (SMZL). 116
CD229 expression on bone marrow plasma cells from patients with multiple myeloma and monoclonal gammopathies of uncertain significance 116
Association of folate transporter SLC19A1 polymorphisms with the outcome of multiple myeloma after chemotherapy and tandem autologous transplantation 115
Mesangiogenic progenitor cells are forced toward the angiogenic fate, in multiple myeloma 114
High-dose zinc oral supplementation after stem cell transplantation causes an increase of TRECs and CD4+ naïve lymphocytes and prevents TTV reactivation 113
The WNT pathway is relevant for the BCR-ABL1-independent resistance in chronic myeloid leukemia 112
Genetic polymorphisms in genes of class switch recombination and multiple myeloma risk and survival: an IMMEnSE study 111
Sorafenib as monotherapy or in association with cytarabine and clofarabine for the treatment of relapsed/refractory FLT3 ITD-positive advanced acute myeloid leukemia 110
TNF-a Polymorphism Modulates the Outcome of Multiple Myeloma Patients Treated with Bortezomib 109
Polymorphisms in xenobiotic transporters ABCB1, ABCG2, ABCC2, ABCC1, ABCC3 and multiple myeloma risk: a case-control study in the context of the International Multiple Myeloma rESEarch (IMMEnSE) consortium. 109
Transitory marrow aplasia during Imatinib therapy in a patient with chronic myeloid leukemia 109
CD45 expression in low-grade non-Hodgkin's lymphomas 108
Optimizing Follow up Schedule for Non Hodgkin Lymphoma' Patients by Multi-Objective Analysis. 107
Myelomatous meningitis evaluated by multiparameter flow cytometry : report of a case and review of the literature 106
The Role of Imaging in Relapse Detection During Follow up: a Fifteen-Year Single Center Experience. 105
Poor prognosis chronic myeloid leukemia with a complex variant Philadelphia translocation, t(9;10;22)(q34;q24;q11) 105
Folate levels in cancer: a vitamin for a new challenge 104
Inherited variation in the xenobiotic transporter pathway and survival of multiple myeloma patients 104
ACUTE T-LYMPHOBLASTIC LEUKEMIA/LYMPHOBLASTIC T-CELL LYMPHOMA. ROLE OF EARLY allo-SCT 104
Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia 103
Risk of multiple myeloma is associated with polymorphisms within telomerase genes and telomere length. 103
ORAL CYCLOPHOSPHAMIDE AND RITUXIMAB IN THE TREATMENT OF MARGINAL ZONE LYMPHOMA 102
CD69 Expression Predicts Favorable Outcome in Multiple Myeloma Patients Treated with VTD 102
Comparison of Bone Marrow Biopsy, Flow Cytometry and PCR Assays To Detect Bone Marrow Involvement in B-Cell Non-Hodgkin Lymphomas. 100
Two Cases of Plasma Cell Leukemia with Atypical Immunophenotype 100
Association of PIM gene translocation and TEL/AML1 rearrangement. 99
MDR1 diplotypes as prognostic markers in multiple myeloma 99
Autologous stem cell transplantation is safe in selected elderly multiple myeloma patients 99
Dipeptidyl-Peptidase 4 (Cd26): a Possible Therapeutic Target in Covid-19 98
Molecular Remission After VTD or TAD As Induction for Multiple Myeloma: Results with Two Different Methods of Analysis 97
A common variant within the HNF1B gene is associated with overall survival of multiple myeloma patients: Results from the IMMEnSE consortium and meta-analysis 97
The Onset of Monoclonal and Oligoclonal Gammopathies Is a Good Prognostic Factor after Allogeneic Stem Cell Transplantation 97
The onset of monoclonal and oligoclonal gammopathies is a good prognostic factor after allogeneic stem cell transplantation 97
Bortezomib and liposomal doxorubicin are highly effective in obtaining the best possible response before autologous transplant for multiple myeloma 96
Complex translocation t(3;9;22)(q21;q34;q11) at diagnosis is a negative prognostic index in chronic myeloid leukemia 96
Genome-wide association study identifies variants at 16p13 associated with survival in multiple myeloma patients. 96
MDR1 C3435T polymorphism indicates a different outcome in advanced multiple myeloma 95
Keys to early diagnosis of cardiac amyloidosis: red flags from clinical, laboratory and imaging findings 95
Stable low IgG levels in relapsed non-Hodgkin's lymphomas 94
Reduction of immunoglobulin levels during imatinib therapy of chronic myeloid leukemia. 94
Folate levels and methylation of CDKI proteins 93
Simultaneous appearance of acute myeloid leukemia in a patient with bilateral primary uveal melanoma 93
Safety and Efficacy of Pegylated Liposomal Doxorubicin In Combination with Dexamethasone and Bortezomib (VMD) or Lenalidomide (RMD) In Multiple Myeloma Refractory/Relapsed Patients 93
Immune Reconstitution after Allogeneic Stem Cell Transplantation: a Pilot Flow-Cytometry Study for T-Cell Sub-Populations 93
MDR1 modulates apoptosis in CD34+ leukemic cells 92
Cardiac light-chain deposition disease relapsing in the transplanted heart 92
Pegylated liposomal doxorubicin in combination with dexamethasone and bortezomib (VMD) or lenalidomide (RMD) in multiple myeloma pretreated patients. 91
Donor-transmitted Triple-Hit Lymphoma in a Renal Allograft Recipient 91
Genetic variants and multiple myeloma risk: IMMEnSE validation of the best reported associations--an extensive replication of the associations from the candidate gene era. 91
Complex translocation t(6;9;22)(p21.1;q34;q11) at diagnosis is a therapy resistance index in chronic myeloid leukaemia. 90
Concomitant translocation t(14;22)(q32;q11) in a case of chronic myeloid leukemia. 90
The Polycomb BMI1 Protein Is Co-expressed With CD26+ in Leukemic Stem Cells of Chronic Myeloid Leukemia 89
Bortezomib with Thalidomide plus Dexamethasone Compared with Thalidomide plus Doxorubicin and Dexamethasone as Induction Therapy in Previously Untreated Multiple Myeloma Patients. 88
PRDI-BF1 and PRDI-BF1P isoform expressions correlate with disease status in multiple myeloma patients 88
Neoplasie degli organi emopoietici e linfatici: peculiarità dell'anziano 87
ZINC ORAL SUPPLEMENTATION INDUCES A SIGNIFICANT RISE OF TRECS AND T CD4+ NAΪVE AND PREVENTS THE INCREASE OF TTV VIRAL LOAD AFTER STEM CELL TRANSPLANTATION: THE ZENITH STUDY 85
Plasma Cell Disorders and Dialysis-Dependent Renal Failure: Safety and Efficacy of Autologous Stem Cell Transplantation 84
Totale 11.730
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.947
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.947
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/20201.550 0 0 0 0 0 281 336 237 264 172 215 45
2020/20211.207 92 76 77 64 114 69 124 91 121 78 107 194
2021/20221.647 44 103 53 103 273 199 59 68 89 59 118 479
2022/20232.110 291 289 136 183 211 229 18 167 345 14 208 19
2023/20241.680 193 215 218 138 267 243 65 35 16 27 97 166
2024/20251.400 19 175 49 290 487 380 0 0 0 0 0 0
Totale 14.770